CoChat
Sign Up
Cited by 102

MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers

Wei, Wei, Wang, Zhi-Yong, Ma, Li-Na, Zhang, Ting-Ting, Cao, Yu, Li, Hao·2020·Frontiers in Molecular Neuroscience
DOI 10.3389/fnmol.2020.00160PMC PMC7471745
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnmol.2020.00160

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miRNAs regulate core pathogenic pathways such as APP processing, tau phosphorylation, inflammation, synaptic plasticity, and metabolism in a cell-type-specific manner.

    “They regulate core pathogenic pathways such as APP processing, tau phosphorylation, inflammation, synaptic plasticity, and metabolism in a cell-type-specific manner (Salta et al., 2016; Li et al., 2024; Wei et al., 2020).”

    From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Wei et al., 2020

  • miR-126 promotes vascular stability and limits barrier permeability by targeting negative regulators of PI3K/AKT and VE-cadherin signaling and by restraining VCAM-1-mediated leukocyte adhesion.

    “Among them, miR-126 is a well-characterized vascular miRNA that promotes vascular stability and limits barrier permeability by targeting negative regulators of PI3K/AKT and VE-cadherin signaling and by restraining VCAM-1–mediated leukocyte adhesion (Fu et al., 2019; Wang et al., 2008; Wei et al., 2020; Yu et al., 2022).”

    From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Wei et al., 2020

  • OLs and OPCs are vulnerable to Aβ toxicity, oxidative stress, and inflammation, leading to impaired myelination and OL death.

    “OLs and their precursor cells (OPCs) are vulnerable to Aβ toxicity, oxidative stress, and inflammation, leading to impaired myelination and OL death (Nasrabady et al., 2018; Wei et al., 2020; Zhou et al., 2022).”

    From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Wei et al., 2020

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 178

  1. Akhter R. Shao Y. Shaw M. Formica S. Khrestian M. Leverenz J. B. (2018). Regulation of ADAM10 by miR-140-5p and potential relevance for Alzheimer’s disease. Neurobiol. Aging 63 110– 119. 10.1016/j.neurobiolaging.2017.11.007 29253717 PMC5800962 · DOI
  2. Alonso A. D. Cohen L. S. Corbo C. Morozova V. ElIdrissi A. Phillips G. (2018). Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability. Front. Cell. Neurosci. 12: 338. 10.3389/fncel.2018.00338 30356756 PMC6189415 · DOI · Paper page
  3. Ameres S. L. Zamore P. D. (2013). Diversifying microRNA sequence and function. Nat. Rev. Mol. Cell Biol. 14 475– 488. 10.1038/nrm3611 23800994 · DOI · Paper page
  4. Arena A. Iyer A. M. Milenkovic I. Kovacs G. G. Ferrer I. Perluigi M. (2017). Developmental expression and dysregulation of miR-146a and miR-155 in down’s syndrome and mouse models of down’s syndrome and Alzheimer’s disease. Curr. Alzheimer Res. 14 1305– 1317. 10.2174/1567205014666170706112701 28720071 · DOI
  5. Augustin R. Endres K. Reinhardt S. Kuhn P.-H. Lichtenthaler S. F. Hansen J. (2012). Computational identification and experimental validation of microRNAs binding to the Alzheimer-related gene ADAM10. BMC Med. Genet. 13: 35. 10.1186/1471-2350-13-35 22594617 PMC3459808 · DOI
  6. Banzhaf-Strathmann J. Benito E. May S. Arzberger T. Tahirovic S. Kretzschmar H. (2014). MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease. EMBO J. 33 1667– 1680. 10.15252/embj.201387576 25001178 PMC4194100 · DOI · Paper page
  7. Barbagallo C. Mostile G. Baglieri G. Giunta F. Luca A. Raciti L. (2020). Specific signatures of serum miRNAs as potential biomarkers to discriminate clinically similar neurodegenerative and vascular-related diseases. Cell. Mol. Neurobiol. 40 531– 546. 10.1007/s10571-019-00751-y 31691877 PMC11448951 · DOI
  8. Barry G. (2014). Integrating the roles of long and small non-coding RNA in brain function and disease. Mol. Psychiatry 19 410– 416. 10.1038/mp.2013.196 24468823 · DOI
  9. Bhatnagar S. Chertkow H. Schipper H. M. Yuan Z. Shetty V. Jenkins S. (2014). Increased microRNA-34c abundance in Alzheimer’s disease circulating blood plasma. Front. Mol. Neurosci. 7: 2. 10.3389/fnmol.2014.00002 24550773 PMC3912349 · DOI
  10. Bhattacharjee S. Zhao Y. Dua P. Rogaev E. I. Lukiw W. J. (2016). microRNA-34a-mediated down-regulation of the microglial-enriched triggering receptor and phagocytosis-sensor TREM2 in age-related macular degeneration. PLoS One 11: e0150211. 10.1371/journal.pone.0150211 26949937 PMC4780721 · DOI · Paper page
  11. Bis J. C. Jian X. Kunkle B. W. Chen Y. Hamilton-Nelson K. L. Bush W. S. (2018). Whole exome sequencing study identifies novel rare and common Alzheimer’s-Associated variants involved in immune response and transcriptional regulation. Mol. Psychiatry 25 1859– 1875. 10.1038/s41380-018-0112-7 30108311 PMC6375806 · DOI · Paper page
  12. Bryniarski K. Ptak W. Martin E. Nazimek K. Szczepanik M. Sanak M. (2015). Free extracellular miRNA functionally targets cells by transfecting exosomes from their companion cells. PLoS One 10: e0122991. 10.1371/journal.pone.0122991 25923429 PMC4414541 · DOI
  13. Bu G. (2009). Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10 333– 344. 10.1038/nrn2620 19339974 PMC2908393 · DOI · Paper page
  14. Cai M. Wang Y. W. Xu S. H. Qiao S. Shu Q. F. Du J. Z. (2018). Regulatory effects of the long noncoding RNA RP11543N12.1 and microRNA3243p axis on the neuronal apoptosis induced by the inflammatory reactions of microglia. Int. J. Mol. Med. 42 1741– 1755. 10.3892/ijmm.2018.3736 29956723 · DOI
  15. Campion D. Pottier C. Nicolas G. Le Guennec K. Rovelet-Lecrux A. (2016). Alzheimer disease: modeling an Abeta-centered biological network. Mol. Psychiatry 21 861– 871. 10.1038/mp.2016.38 27021818 · DOI
  16. Cao F. Liu Z. Sun G. (2020). Diagnostic value of miR-193a-3p in Alzheimer’s disease and miR-193a-3p attenuates amyloid-beta induced neurotoxicity by targeting PTEN. Exp. Gerontol. 130: 110814. 10.1016/j.exger.2019.110814 31857133 · DOI
  17. Cech T. R. Steitz J. A. (2014). The noncoding RNA revolution-trashing old rules to forge new ones. Cell 157 77– 94. 10.1016/j.cell.2014.03.008 24679528 · DOI · Paper page
  18. Cha D. J. Mengel D. Mustapic M. Liu W. Selkoe D. J. Kapogiannis D. (2019). miR-212 and miR-132 Are Downregulated In Neurally Derived Plasma Exosomes Of Alzheimer’s patients. Front. Neurosci. 13: 1208. 10.3389/fnins.2019.01208 31849573 PMC6902042 · DOI
  19. Chen F. Z. Zhao Y. Chen H. Z. (2019). MicroRNA-98 reduces amyloid beta-protein production and improves oxidative stress and mitochondrial dysfunction through the Notch signaling pathway via HEY2 in Alzheimer’s disease mice. Int. J. Mol. Med. 43 91– 102. 10.3892/ijmm.2018.3957 30365070 PMC6257854 · DOI
  20. Cheng L. Doecke J. D. Sharples R. A. Villemagne V. L. Fowler C. J. Rembach A. (2015). Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Mol. Psychiatry 20 1188– 1196. 10.1038/mp.2014.127 25349172 · DOI · Paper page
  21. Cirrito J. R. Kang J. E. Lee J. Stewart F. R. Verges D. K. Silverio L. M. (2008). Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58 42– 51. 10.1016/j.neuron.2008.02.003 18400162 PMC2390913 · DOI · Paper page
  22. Corder E. H. Saunders A. M. Strittmatter W. J. Schmechel D. E. Gaskell P. C. Small G. W. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261 921– 923. 10.1126/science.8346443 8346443 · DOI · Paper page
  23. Cosin-Tomas M. Antonell A. Llado A. Alcolea D. Fortea J. Ezquerra M. (2017). Plasma miR-34a-5p and miR-545-3p as early biomarkers of Alzheimer’s disease: potential and limitations. Mol. Neurobiol. 54 5550– 5562. 10.1007/s12035-016-0088-8 27631879 · DOI
  24. Crimins J. L. Pooler A. Polydoro M. Luebke J. I. Spires-Jones T. L. (2013). The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer’s disease. Ageing Res. Rev. 12 757– 763. 10.1016/j.arr.2013.03.002 23528367 PMC3735866 · DOI
  25. Dangla-Valls A. Molinuevo J. L. Altirriba J. Sanchez-Valle R. Alcolea D. Fortea J. (2017). CSF microRNA profiling in Alzheimer’s disease: a screening and validation study. Mol. Neurobiol. 54 6647– 6654. 10.1007/s12035-016-0106-x 27738874 · DOI
  26. Das S. Ferlito M. Kent O. A. Fox-Talbot K. Wang R. Liu D. (2012). Nuclear miRNA regulates the mitochondrial genome in the heart. Circ. Res. 110 1596– 1603. 10.1161/circresaha.112.267732 22518031 PMC3390752 · DOI
  27. Das U. Wang L. Ganguly A. Saikia J. M. Wagner S. L. Koo E. H. (2016). Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway. Nat. Neurosci. 19 55– 64. 10.1038/nn.4188 26642089 PMC4782935 · DOI
  28. Davila-Bouziguet E. Targa-Fabra G. Avila J. Soriano E. Pascual M. (2019). Differential accumulation of Tau phosphorylated at residues Thr231, Ser262 and Thr205 in hippocampal interneurons and its modulation by Tau mutations (VLW) and amyloid-beta peptide. Neurobiol. Dis. 125 232– 244. 10.1016/j.nbd.2018.12.006 30553886 · DOI
  29. Dragomir M. P. Knutsen E. Calin G. A. (2018). SnapShot: unconventional miRNA functions. Cell 174 1038.e1– 1038.e1. 10.1016/j.cell.2018.07.040 30096304 · DOI
  30. Edwards F. A. (2019). A Unifying Hypothesis for Alzheimer’s disease: from plaques to neurodegeneration. Trends Neurosci. 42 310– 322. 10.1016/j.tins.2019.03.003 31006494 · DOI · Paper page
  31. Eggert S. Thomas C. Kins S. Hermey G. (2018). Trafficking in Alzheimer’s disease: modulation of APP transport and processing by the transmembrane proteins LRP1, SorLA, SorCS1c, sortilin, and calsyntenin. Mol. Neurobiol. 55 5809– 5829. 10.1007/s12035-017-0806-x 29079999 · DOI
  32. Friedman R. C. Farh K. K. Burge C. B. Bartel D. P. (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19 92– 105. 10.1101/gr.082701.108 18955434 PMC2612969 · DOI · Paper page
  33. Geng L. Zhang T. Liu W. Chen Y. (2018). Inhibition of miR-128 abates abeta-mediated cytotoxicity by targeting PPAR-gamma via NF-kappaB inactivation in primary mouse cortical neurons and Neuro2a cells. Yonsei Med. J. 59 1096– 1106. 10.3349/ymj.2018.59.9.1096 30328325 PMC6192880 · DOI · Paper page
  34. Ghasemi-Kasman M. Shojaei A. Gol M. Moghadamnia A. A. Baharvand H. Javan M. (2018). miR-302/367-induced neurons reduce behavioral impairment in an experimental model of Alzheimer’s disease. Mol. Cell. Neurosci. 86 50– 57. 10.1016/j.mcn.2017.11.012 29174617 · DOI
  35. Giau V. V. Bagyinszky E. An S. S. A. (2019). Potential fluid biomarkers for the diagnosis of mild cognitive impairment. Int. J. Mol. Sci. 20: 4149. 10.3390/ijms20174149 31450692 PMC6747411 · DOI
  36. Glenner G. G. Wong C. W. (1984). Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120 885– 890. 10.1016/s0006-291x(84)80190-4 6375662 · DOI · Paper page
  37. Goate A. Chartier-Harlin M. C. Mullan M. Brown J. Crawford F. Fidani L. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349 704– 706. 10.1038/349704a0 1671712 · DOI · Paper page
  38. Goedert M. Spillantini M. G. Cairns N. J. Crowther R. A. (1992). Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8 159– 168. 10.1016/0896-6273(92)90117-v 1530909 · DOI
  39. Goodall E. F. Heath P. R. Bandmann O. Kirby J. Shaw P. J. (2013). Neuronal dark matter: the emerging role of microRNAs in neurodegeneration. Front. Cell. Neurosci. 7: 178. 10.3389/fncel.2013.00178 24133413 PMC3794211 · DOI · Paper page
  40. Grasso M. Piscopo P. Talarico G. Ricci L. Crestini A. Tosto G. (2019). Plasma microRNA profiling distinguishes patients with frontotemporal dementia from healthy subjects. Neurobiol. Aging 84 240.e1– 240.e12. 10.1016/j.neurobiolaging.2019.01.024 30826067 · DOI
  41. Groot M. Lee H. (2020). Sorting mechanisms for MicroRNAs into extracellular vesicles and their associated diseases. Cells 9: 1044. 10.3390/cells9041044 32331346 PMC7226101 · DOI
  42. Guo R. Fan G. Zhang J. Wu C. Du Y. Ye H. (2017). A 9-microRNA signature in serum serves as a noninvasive biomarker in early diagnosis of Alzheimer’s disease. J. Alzheimers Dis. 60 1365– 1377. 10.3233/JAD-170343 29036818 · DOI
  43. Haass C. Kaether C. Thinakaran G. Sisodia S. (2012). Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2: a006270. 10.1101/cshperspect.a006270 22553493 PMC3331683 · DOI · Paper page
  44. Hajjri S. N. Sadigh-Eteghad S. Mehrpour M. Moradi F. Shanehbandi D. Mehdizadeh M. (2020). Beta-amyloid-dependent mirnas as circulating biomarkers in Alzheimer’s disease: a preliminary report. J. Mol. Neurosci. 70 871– 877. 10.1007/s12031-020-01511-0 32306293 · DOI
  45. Hara N. Kikuchi M. Miyashita A. Hatsuta H. Saito Y. Kasuga K. (2017). Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer’s disease. Acta Neuropathol. Commun. 5: 10. 10.1186/s40478-017-0414-z 28137310 PMC5282710 · DOI
  46. Hardy J. Selkoe D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297 353– 356. 10.1126/science.1072994 12130773 · DOI · Paper page
  47. Hardy J. A. Higgins G. A. (1992). Alzheimer’s disease: the amyloid cascade hypothesis. Science 256 184– 185. 10.1126/science.1566067 1566067 · DOI · Paper page
  48. Hernandez-Rapp J. Smith P. Y. Filali M. Goupil C. Planel E. Magill S. T. (2015). Memory formation and retention are affected in adult miR-132/212 knockout mice. Behav. Brain Res. 287 15– 26. 10.1016/j.bbr.2015.03.032 25813747 · DOI
  49. Higaki S. Muramatsu M. Matsuda A. Matsumoto K. Satoh J. I. Michikawa M. (2018). Defensive effect of microRNA-200b/c against amyloid-beta peptide-induced toxicity in Alzheimer’s disease models. PLoS One 13: e0196929. 10.1371/journal.pone.0196929 29738527 PMC5940223 · DOI
  50. Hu L. Zhang R. Yuan Q. Gao Y. Yang M. Q. Zhang C. (2018). The emerging role of microRNA-4487/6845-3p in Alzheimer’s disease pathologies is induced by Abeta25-35 triggered in SH-SY5Y cell. BMC Syst. Biol. 12: 119. 10.1186/s12918-018-0633-3 30547775 PMC6293494 · DOI
  51. Huang Q. Voloudakis G. Ren Y. Yoon Y. Zhang E. Kajiwara Y. (2018). Presenilin1/gamma-secretase protects neurons from glucose deprivation-induced death by regulating miR-212 and PEA15. FASEB J. 32 243– 253. 10.1096/fj.201700447RR 28855274 PMC5731132 · DOI
  52. Ipsaro J. J. Joshua-Tor L. (2015). From guide to target: molecular insights into eukaryotic RNA-interference machinery. Nat. Struct. Mol. Biol. 22 20– 28. 10.1038/nsmb.2931 25565029 PMC4450863 · DOI · Paper page
  53. Iqbal K. Liu F. Gong C. X. (2016). Tau and neurodegenerative disease: the story so far. Nat. Rev. Neurol. 12 15– 27. 10.1038/nrneurol.2015.225 26635213 · DOI · Paper page
  54. Jain G. Stuendl A. Rao P. Berulava T. Pena Centeno T. Kaurani L. (2019). A combined miRNA-piRNA signature to detect Alzheimer’s disease. Transl. Psychiatry 9: 250. 10.1038/s41398-019-0579-2 31591382 PMC6779890 · DOI · Paper page
  55. Jia L. H. Liu Y. N. (2016). Downregulated serum miR-223 servers as biomarker in Alzheimer’s disease. Cell Biochem. Funct. 34 233– 237. 10.1002/cbf.3184 27027823 · DOI · Paper page
  56. Jiang Y. Xu B. Chen J. Sui Y. Ren L. Li J. (2018). Micro-RNA-137 inhibits tau hyperphosphorylation in Alzheimer’s disease and targets the CACNA1C gene in transgenic mice and human neuroblastoma SH-SY5Y cells. Med. Sci. Monit. 24 5635– 5644. 10.12659/msm.908765 30102687 PMC6104547 · DOI
  57. Jiao Y. Kong L. Yao Y. Li S. Tao Z. Yan Y. (2016). Osthole decreases beta amyloid levels through up-regulation of miR-107 in Alzheimer’s disease. Neuropharmacology 108 332– 344. 10.1016/j.neuropharm.2016.04.046 27143098 · DOI
  58. Jin Y. Tu Q. Liu M. (2018). MicroRNA125b regulates Alzheimer’s disease through SphK1 regulation. Mol. Med. Rep. 18 2373– 2380. 10.3892/mmr.2018.9156 29901156 · DOI
  59. Jinek M. Doudna J. A. (2009). A three-dimensional view of the molecular machinery of RNA interference. Nature 457 405– 412. 10.1038/nature07755 19158786 · DOI
  60. Kaether C. Schmitt S. Willem M. Haass C. (2006). Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface. Traffic 7 408– 415. 10.1111/j.1600-0854.2006.00396.x 16536739 · DOI
  61. Kang Q. Xiang Y. Li D. Liang J. Zhang X. Zhou F. (2017). MiR-124-3p attenuates hyperphosphorylation of Tau protein-induced apoptosis via caveolin-1-PI3K/Akt/GSK3beta pathway in N2a/APP695swe cells. Oncotarget 8 24314– 24326. 10.18632/oncotarget.15149 28186985 PMC5421849 · DOI
  62. Kao Y. C. Wang I. F. Tsai K. J. (2018). miRNA-34c overexpression causes dendritic loss and memory decline. Int. J. Mol. Sci. 19: 2323. 10.3390/ijms19082323 30096777 PMC6121231 · DOI
  63. Kawashima H. Numakawa T. Kumamaru E. Adachi N. Mizuno H. Ninomiya M. (2010). Glucocorticoid attenuates brain-derived neurotrophic factor-dependent upregulation of glutamate receptors via the suppression of microRNA-132 expression. Neuroscience 165 1301– 1311. 10.1016/j.neuroscience.2009.11.057 19958814 · DOI
  64. Keller A. Backes C. Haas J. Leidinger P. Maetzler W. Deuschle C. (2016). Validating Alzheimer’s disease micro RNAs using next-generation sequencing. Alzheimers Dement. 12 565– 576. 10.1016/j.jalz.2015.12.012 26806387 · DOI
  65. Kenny A. McArdle H. Calero M. Rabano A. Madden S. F. Adamson K. (2019). Elevated plasma microRNA-206 levels predict cognitive decline and progression to dementia from mild cognitive impairment. Biomolecules 9: 734. 10.3390/biom9110734 31766231 PMC6920950 · DOI
  66. Kiko T. Nakagawa K. Tsuduki T. Furukawa K. Arai H. Miyazawa T. (2014). MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease. J. Alzheimers Dis. 39 253– 259. 10.3233/JAD-130932 24157723 · DOI · Paper page
  67. Ko C. Y. Chu Y. Y. Narumiya S. Chi J. Y. Furuyashiki T. Aoki T. (2015). CCAAT/enhancer-binding protein delta/miR135a/thrombospondin 1 axis mediates PGE2-induced angiogenesis in Alzheimer’s disease. Neurobiol. Aging 36 1356– 1368. 10.1016/j.neurobiolaging.2014.11.020 25554493 · DOI
  68. Konietzko U. (2012). AICD nuclear signaling and its possible contribution to Alzheimer’s disease. Curr. Alzheimer Res. 9 200– 216. 10.2174/156720512799361673 21605035 · DOI
  69. Kuchibhotla K. V. Goldman S. T. Lattarulo C. R. Wu H. Y. Hyman B. T. Bacskai B. J. (2008). Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59 214– 225. 10.1016/j.neuron.2008.06.008 18667150 PMC2578820 · DOI · Paper page
  70. Kumar S. Reddy P. H. (2018). MicroRNA-455-3p as a potential biomarker for Alzheimer’s disease: an update. Front. Aging Neurosci. 10: 41. 10.3389/fnagi.2018.00041 29527164 PMC5829054 · DOI
  71. Kumar S. Reddy P. H. (2019). A new discovery of MicroRNA-455-3p in Alzheimer’s disease. J. Alzheimers Dis. 72 S117– S130. 10.3233/JAD-190583 31524168 · DOI
  72. Kumar S. Vijayan M. Reddy P. H. (2017). MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease. Hum. Mol. Genet. 26 3808– 3822. 10.1093/hmg/ddx267 28934394 PMC6075184 · DOI · Paper page
  73. Kumar-Singh S. Theuns J. Van Broeck B. Pirici D. Vennekens K. Corsmit E. (2006). Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum. Mutat. 27 686– 695. 10.1002/humu.20336 16752394 · DOI
  74. Lane C. A. Hardy J. Schott J. M. (2018). Alzheimer’s disease. Eur. J. Neurol. 25 59– 70. 10.1111/ene.13439 28872215 · DOI · Paper page
  75. Lauressergues D. Couzigou J. M. Clemente H. S. Martinez Y. Dunand C. Bécard G. (2015). Primary transcripts of microRNAs encode regulatory peptides. Nature 520 90– 93. 10.1038/nature14346 25807486 · DOI
  76. Lee B. K. Kim M. H. Lee S. Y. Son S. J. Hong C. H. Jung Y. S. (2020). Downregulated platelet miR-1233-5p in patients with Alzheimer’s pathologic change with mild cognitive impairment is associated with abeta-induced platelet activation via P-Selectin. J. Clin. Med. 9: 1624. 10.3390/jcm9061642 32485903 PMC7357133 · DOI
  77. Lee K. Kim H. An K. Kwon O. B. Park S. Cha J. H. (2016). Replenishment of microRNA-188-5p restores the synaptic and cognitive deficits in 5XFAD mouse model of Alzheimer’s disease. Sci. Rep. 6 34433. 10.1038/srep34433 27708404 PMC5052619 · DOI
  78. Lee S. Hall G. F. Shea T. B. (2011). Potentiation of tau aggregation by cdk5 and GSK3beta. J. Alzheimers Dis. 26 355– 364. 10.3233/jad-2011-102016 21677377 · DOI
  79. Lee S. Mankhong S. Kang J. H. (2019). Extracellular vesicle as a source of Alzheimer’s biomarkers: opportunities and challenges. Int. J. Mol. Sci. 20: 1728. 10.3390/ijms20071728 30965555 PMC6479979 · DOI
  80. Lehmann S. M. Kruger C. Park B. Derkow K. Rosenberger K. Baumgart J. (2012). An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat. Neurosci. 15 827– 835. 10.1038/nn.3113 22610069 · DOI · Paper page
  81. Leidinger P. Backes C. Deutscher S. Schmitt K. Mueller S. C. Frese K. (2013). A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 14: R78. 10.1186/gb-2013-14-7-r78 23895045 PMC4053778 · DOI
  82. Li D. Li Y. P. Li Y. X. Zhu X. H. Du X. G. Zhou M. (2018). Effect of regulatory network of exosomes and microRNAs on neurodegenerative diseases. Chin. Med. J. 131 2216– 2225. 10.4103/0366-6999.240817 30203797 PMC6144844 · DOI
  83. Li H. H. Lin S. L. Huang C. N. Lu F. J. Chiu P. Y. Huang W. N. (2016). miR-302 attenuates amyloid-beta-induced neurotoxicity through activation of Akt signaling. J. Alzheimers Dis. 50 1083– 1098. 10.3233/jad-150741 26890744 · DOI
  84. Li J. Chen W. Yi Y. Tong Q. (2019). miR-219-5p inhibits tau phosphorylation by targeting TTBK1 and GSK-3beta in Alzheimer’s disease. J. Cell. Biochem. 120 9936– 9946. 10.1002/jcb.28276 30556160 · DOI
  85. Li X. Wang Z. Tan L. Wang Y. Lu C. Chen R. (2017). Correcting miR92a-vGAT-mediated GABAergic dysfunctions rescues human tau-induced anxiety in mice. Mol. Ther. 25 140– 152. 10.1016/j.ymthe.2016.10.010 28129110 PMC5363302 · DOI
  86. Liu W. Zhao J. Lu G. (2016). miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer’s disease. Biochem. Biophys. Res. Commun. 478 852– 857. 10.1016/j.bbrc.2016.08.037 27520374 · DOI
  87. Liu Y. He X. Li Y. Wang T. (2018). Cerebrospinal fluid CD4+ T lymphocyte-derived miRNA-let-7b can enhances the diagnostic performance of Alzheimer’s disease biomarkers. Biochem. Biophys. Res. Commun. 495 1144– 1150. 10.1016/j.bbrc.2017.11.122 29170128 · DOI
  88. Long J. M. Lahiri D. K. (2011). MicroRNA-101 downregulates Alzheimer’s amyloid-beta precursor protein levels in human cell cultures and is differentially expressed. Biochem. Biophys. Res. Commun. 404 889– 895. 10.1016/j.bbrc.2010.12.053 21172309 PMC3372402 · DOI
  89. Long J. M. Maloney B. Rogers J. T. Lahiri D. K. (2019). Novel upregulation of amyloid-beta precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5′-untranslated region: implications in Alzheimer’s disease. Mol. Psychiatry 24 345– 363. 10.1038/s41380-018-0266-3 30470799 PMC6514885 · DOI · Paper page
  90. Long J. M. Ray B. Lahiri D. K. (2014). MicroRNA-339-5p down-regulates protein expression of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J. Biol. Chem. 289 5184– 5198. 10.1074/jbc.M113.518241 24352696 PMC3931075 · DOI · Paper page
  91. Lopes J. P. Agostinho P. (2011). Cdk5: multitasking between physiological and pathological conditions. Prog. Neurobiol. 94 49– 63. 10.1016/j.pneurobio.2011.03.006 21473899 · DOI
  92. Lugli G. Cohen A. M. Bennett D. A. Shah R. C. Fields C. J. Hernandez A. G. (2015). Plasma Exosomal miRNAs in Persons with and without Alzheimer disease: altered Expression and Prospects for Biomarkers. PLoS One 10: e0139233. 10.1371/journal.pone.0139233 26426747 PMC4591334 · DOI
  93. Lusardi T. A. Phillips J. I. Wiedrick J. T. Harrington C. A. Lind B. Lapidus J. A. (2017). MicroRNAs in human cerebrospinal fluid as biomarkers for Alzheimer’s disease. J. Alzheimers Dis. 55 1223– 1233. 10.3233/JAD-160835 27814298 PMC5587208 · DOI
  94. Ma X. Liu L. Meng J. (2017). MicroRNA-125b promotes neurons cell apoptosis and Tau phosphorylation in Alzheimer’s disease. Neurosci. Lett. 661 57– 62. 10.1016/j.neulet.2017.09.043 28947385 · DOI
  95. Madadi S. Saidijam M. Yavari B. Soleimani M. (2020). Downregulation of serum miR-106b: a potential biomarker for Alzheimer disease. Arch. Physiol. Biochem. [Epub ahead of print]. 10.1080/13813455.2020.1734842 32141790 · DOI
  96. Mairet-Coello G. Courchet J. Pieraut S. Courchet V. Maximov A. Polleux F. (2013). The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Abeta oligomers through Tau phosphorylation. Neuron 78 94– 108. 10.1016/j.neuron.2013.02.003 23583109 PMC3784324 · DOI · Paper page
  97. Manzine P. R. Pelucchi S. Horst M. A. Vale F. A. C. Pavarini S. C. I. Audano M. (2018). microRNA 221 Targets ADAM10 mRNA and is Downregulated in Alzheimer’s Disease. J. Alzheimers Dis. 61 113– 123. 10.3233/jad-170592 29036829 · DOI
  98. Marchegiani F. Matacchione G. Ramini D. Marcheselli F. Recchioni R. Casoli T. (2019). Diagnostic performance of new and classic CSF biomarkers in agerelated dementias. Aging 11 2420– 2429. 10.18632/aging.101925 31029057 PMC6520009 · DOI
  99. Matsui M. Chu Y. Zhang H. Gagnon K. T. Shaikh S. Kuchimanchi S. (2013). Promoter RNA links transcriptional regulation of inflammatory pathway genes. Nucleic Acids Res. 41 10086– 10109. 10.1093/nar/gkt777 23999091 PMC3905862 · DOI
  100. McKeever P. M. Schneider R. Taghdiri F. Weichert A. Multani N. Brown R. A. (2018). MicroRNA expression levels are altered in the cerebrospinal fluid of patients with young-onset Alzheimer’s disease. Mol. Neurobiol. 55 8826– 8841. 10.1007/s12035-018-1032-x 29603092 PMC6208843 · DOI
  101. Mezache L. Mikhail M. Garofalo M. Nuovo G. J. (2015). Reduced miR-512 and the elevated expression of its targets cFLIP and MCL1 localize to neurons with hyperphosphorylated tau protein in Alzheimer disease. Appl. Immunohistochem. Mol. Morphol. 23 615– 623. 10.1097/pai.0000000000000147 26258756 · DOI
  102. Millan M. J. (2017). Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer’s disease: an integrative review. Prog. Neurobiol. 156 1– 68. 10.1016/j.pneurobio.2017.03.004 28322921 · DOI
  103. Modi P. K. Jaiswal S. Sharma P. (2016). Regulation of Neuronal Cell Cycle and Apoptosis by MicroRNA 34a. Mol. Cell. Biol. 36 84– 94. 10.1128/mcb.00589-15 26459758 PMC4702589 · DOI
  104. Moncini S. Lunghi M. Valmadre A. Grasso M. Del Vescovo V. Riva P. (2017). The miR-15/107 family of microRNA genes regulates CDK5R1/p35 with implications for alzheimer’s disease pathogenesis. Mol. Neurobiol. 54 4329– 4342. 10.1007/s12035-016-0002-4 27343180 · DOI
  105. Muller M. Jakel L. Bruinsma I. B. Claassen J. A. Kuiperij H. B. Verbeek M. M. (2016). MicroRNA-29a is a candidate biomarker for Alzheimer’s disease in cell-free cerebrospinal fluid. Mol. Neurobiol. 53 2894– 2899. 10.1007/s12035-015-9156-8 25895659 PMC4902829 · DOI
  106. Müller M. Jäkel L. Bruinsma I. B. Claassen J. A. Kuiperij H. B. Verbeek M. M. (2016). MicroRNA-29a is a candidate biomarker for alzheimer’s disease in cell-free cerebrospinal fluid. Mol. Neurobiol. 53 2894– 2899. 25895659 PMC4902829
  107. Muller M. Kuiperij H. B. Claassen J. A. Kusters B. Verbeek M. M. (2014). MicroRNAs in Alzheimer’s disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol. Aging 35 152– 158. 10.1016/j.neurobiolaging.2013.07.005 23962497 · DOI
  108. Nayak D. Roth T. L. McGavern D. B. (2014). Microglia development and function. Annu. Rev. Immunol. 32 367– 402. 10.1146/annurev-immunol-032713-120240 24471431 PMC5001846 · DOI · Paper page
  109. Nelson P. T. Wang W. X. (2010). MiR-107 is reduced in Alzheimer’s disease brain neocortex: validation study. J. Alzheimers Dis. 21 75– 79. 10.3233/jad-2010-091603 20413881 PMC2910235 · DOI · Paper page
  110. Nie C. Sun Y. Zhen H. Guo M. Ye J. Liu Z. (2020). Differential expression of plasma Exo-miRNA in neurodegenerative diseases by next-generation sequencing. Front. Neurosci. 14: 438. 10.3389/fnins.2020.00438 32457573 PMC7227778 · DOI
  111. Parhizkar S. Arzberger T. Brendel M. Kleinberger G. Deussing M. Focke C. (2019). Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat. Neurosci. 22 191– 204. 10.1038/s41593-018-0296-9 30617257 PMC6417433 · DOI · Paper page
  112. Pena-Bautista C. Baquero M. Vento M. Chafer-Pericas C. (2019). Omics-based biomarkers for the early alzheimer disease diagnosis and reliable therapeutic targets development. Curr. Neuropharmacol. 17 630– 647. 10.2174/1570159X16666180926123722 30255758 PMC6712290 · DOI
  113. Penke B. Bogar F. Paragi G. Gera J. Fulop L. (2019). Key peptides and proteins in Alzheimer’s disease. Curr. Protein Pept. Sci. 20 577– 599. 10.2174/1389203720666190103123434 30605056 · DOI
  114. Pichler S. Gu W. Hartl D. Gasparoni G. Leidinger P. Keller A. (2017). The miRNome of Alzheimer’s disease: consistent downregulation of the miR-132/212 cluster. Neurobiol. Aging 50 167.e1– 167.e10. 10.1016/j.neurobiolaging.2016.09.019 27816213 · DOI
  115. Piscopo P. Grasso M. Puopolo M. D’Acunto E. Talarico G. Crestini A. (2018). Circulating miR-127-3p as a potential biomarker for differential diagnosis in frontotemporal dementia. J. Alzheimers Dis. 65 455– 464. 10.3233/JAD-180364 30056425 · DOI
  116. Piscopo P. Lacorte E. Feligioni M. Mayer F. Crestini A. Piccolo L. (2019). MicroRNAs and mild cognitive impairment: a systematic review. Ageing Res. Rev. 50 131– 141. 10.1016/j.arr.2018.11.005 30472218 · DOI
  117. Prendecki M. Florczak-Wyspianska J. Kowalska M. Ilkowski J. Grzelak T. Bialas K. (2019). APOE genetic variants and apoE, miR-107 and miR-650 levels in Alzheimer’s disease. Folia Neuropathol. 57 106– 116. 10.5114/fn.2019.84828 31556571 · DOI
  118. Ren R. J. Zhang Y. F. Dammer E. B. Zhou Y. Wang L. L. Liu X. H. (2016). Peripheral blood MicroRNA expression profiles in Alzheimer’s disease: screening, validation, association with clinical phenotype and implications for molecular mechanism. Mol. Neurobiol. 53 5772– 5781. 10.1007/s12035-015-9484-8 26497032 · DOI
  119. Riancho J. Vazquez-Higuera J. L. Pozueta A. Lage C. Kazimierczak M. Bravo M. (2017). MicroRNA profile in patients with Alzheimer’s disease: analysis of miR-9-5p and miR-598 in raw and exosome enriched cerebrospinal fluid samples. J. Alzheimers Dis. 57 483– 491. 10.3233/JAD-161179 28269782 · DOI · Paper page
  120. Roher A. E. Kokjohn T. A. Clarke S. G. Sierks M. R. Maarouf C. L. Serrano G. E. (2017). APP/Abeta structural diversity and Alzheimer’s disease pathogenesis. Neurochem. Int. 110 1– 13. 10.1016/j.neuint.2017.08.007 28811267 PMC5688956 · DOI
  121. Rosenberg R. N. Lambracht-Washington D. Yu G. Xia W. (2016). Genomics of Alzheimer disease: a review. JAMA Neurol. 73 867– 874. 10.1001/jamaneurol.2016.0301 27135718 PMC6759853 · DOI
  122. Ross S. P. Baker K. E. Fisher A. Hoff L. Pak E. S. Murashov A. K. (2018). miRNA-431 prevents amyloid-beta-induced synapse loss in neuronal cell culture model of Alzheimer’s disease by silencing kremen1. Front. Cell. Neurosci. 12: 87. 10.3389/fncel.2018.00087 29643768 PMC5883862 · DOI
  123. Rovelet-Lecrux A. Hannequin D. Raux G. Le Meur N. Laquerriere A. Vital A. (2006). APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38 24– 26. 10.1038/ng1718 16369530 · DOI
  124. Salta E. De Strooper B. (2017). microRNA-132: a key noncoding RNA operating in the cellular phase of Alzheimer’s disease. FASEB J. 31 424– 433. 10.1096/fj.201601308 28148775 · DOI
  125. Salta E. Sierksma A. Vanden Eynden E. De Strooper B. (2016). miR-132 loss de-represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer’s brain. EMBO Mol. Med. 8 1005– 1018. 10.15252/emmm.201606520 27485122 PMC5009807 · DOI · Paper page
  126. Salter M. W. Beggs S. (2014). Sublime microglia: expanding roles for the guardians of the CNS. Cell 158 15– 24. 10.1016/j.cell.2014.06.008 24995975 · DOI · Paper page
  127. Sanabria-Castro A. Alvarado-Echeverria I. Monge-Bonilla C. (2017). Molecular pathogenesis of Alzheimer’s disease: an update. Ann. Neurosci. 24 46– 54. 10.1159/000464422 28588356 PMC5448443 · DOI
  128. Santa-Maria I. Alaniz M. E. Renwick N. Cela C. Fulga T. A. Van Vactor D. (2015). Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J. Clin. Invest. 125 681– 686. 10.1172/jci78421 25574843 PMC4319412 · DOI
  129. Schwarz D. S. Zamore P. D. (2002). Why do miRNAs live in the miRNP? Genes Dev. 16 1025– 1031. 10.1101/gad.992502 12000786 · DOI
  130. Shi Z. Zhang K. Zhou H. Jiang L. Xie B. Wang R. (2020). Increased miR-34c mediates synaptic deficits by targeting synaptotagmin 1 through ROS-JNK-p53 pathway in Alzheimer’s disease. Aging Cell 19: e13125. 10.1111/acel.13125 32092796 PMC7059146 · DOI
  131. Shu R. Wong W. Ma Q. H. Yang Z. Z. Zhu H. Liu F. J. (2015). APP intracellular domain acts as a transcriptional regulator of miR-663 suppressing neuronal differentiation. Cell Death Dis. 6: e1651. 10.1038/cddis.2015.10 25695604 PMC4669786 · DOI
  132. Siedlecki-Wullich D. Catala-Solsona J. Fabregas C. Hernandez I. Clarimon J. Lleo A. (2019). Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer’s disease. Alzheimers Res. Ther. 11: 46. 10.1186/s13195-019-0501-4 31092279 PMC6521366 · DOI
  133. Sierksma A. Lu A. Salta E. Vanden Eynden E. Callaerts-Vegh Z. D’Hooge R. (2018). Deregulation of neuronal miRNAs induced by amyloid-beta or TAU pathology. Mol. Neurodegener. 13: 54. 10.1186/s13024-018-0285-1 30314521 PMC6186090 · DOI · Paper page
  134. Smith P. Y. Hernandez-Rapp J. Jolivette F. Lecours C. Bisht K. Goupil C. (2015). miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Hum. Mol. Genet. 24 6721– 6735. 10.1093/hmg/ddv377 26362250 PMC4634376 · DOI
  135. Sohrabifar N. Gharesouran J. Talebi M. Ghojazadeh M. Mohaddes Ardebili S. M. (2015). Association of CLU and TLR2 gene polymorphisms with late-onset Alzheimer disease in a northwestern Iranian population. Turk. J. Med. Sci. 45 1082– 1086. 10.3906/sag-1406-64 26738351 · DOI
  136. Souza V. C. Morais G. S. Jr. Henriques A. D. Machado-Silva W. Perez D. I. V. Brito C. J. (2020). Whole-blood levels of MicroRNA-9 are decreased in patients with late-onset Alzheimer disease. Am. J. Alzheimers Dis. Other Demen. 35: 1533317520911573. 10.1177/1533317520911573 32301334 PMC10623914 · DOI
  137. Swarbrick S. Wragg N. Ghosh S. Stolzing A. (2019). Systematic review of miRNA as biomarkers in Alzheimer’s disease. Mol. Neurobiol. 56 6156– 6167. 10.1007/s12035-019-1500-y 30734227 PMC6682547 · DOI
  138. Takousis P. Sadlon A. Schulz J. Wohlers I. Dobricic V. Middleton L. (2019). Differential expression of microRNAs in Alzheimer’s disease brain, blood, and cerebrospinal fluid. Alzheimers Dement. 15 1468– 1477. 10.1016/j.jalz.2019.06.4952 31495604 · DOI
  139. Tan L. Yu J. T. Liu Q. Y. Tan M. S. Zhang W. Hu N. (2014). Circulating miR-125b as a biomarker of Alzheimer’s disease. J. Neurol. Sci. 336 52– 56. 10.1016/j.jns.2013.10.002 24139697 · DOI
  140. Tang Y. Bao J. S. Su J. H. Huang W. (2017). MicroRNA-139 modulates Alzheimer’s-associated pathogenesis in SAMP8 mice by targeting cannabinoid receptor type 2. Genet. Mol. Res. 16: gmr16019166. 10.4238/gmr16019166 28218780 · DOI
  141. Tao Y. Han Y. Yu L. Wang Q. Leng S. X. Zhang H. (2020). The predicted key molecules, functions, and pathways that bridge mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Front. Neurol. 11: 233. 10.3389/fneur.2020.00233 32308643 PMC7145962 · DOI
  142. van den Berg M. M. J. Krauskopf J. Ramaekers J. G. Kleinjans J. C. S. Prickaerts J. Briede J. J. (2020). Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. Prog. Neurobiol. 185: 101732. 10.1016/j.pneurobio.2019.101732 31816349 · DOI
  143. Villa C. Ridolfi E. Fenoglio C. Ghezzi L. Vimercati R. Clerici F. (2013). Expression of the transcription factor Sp1 and its regulatory hsa-miR-29b in peripheral blood mononuclear cells from patients with Alzheimer’s disease. J. Alzheimers Dis. 35 487– 494. 10.3233/JAD-122263 23435408 · DOI
  144. Wang G. Huang Y. Wang L. L. Zhang Y. F. Xu J. Zhou Y. (2016). MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer’s disease. Sci. Rep. 6: 26697. 10.1038/srep26697 27221467 PMC4879631 · DOI
  145. Wang K. Yuan Y. Cho J. H. McClarty S. Baxter D. Galas D. J. (2012). Comparing the MicroRNA spectrum between serum and plasma. PLoS One 7: e41561. 10.1371/journal.pone.0041561 22859996 PMC3409228 · DOI
  146. Wang L. Liu J. Wang Q. Jiang H. Zeng L. Li Z. (2019). MicroRNA-200a-3p mediates neuroprotection in alzheimer-related deficits and attenuates amyloid-beta overproduction and tau hyperphosphorylation via coregulating BACE1 and PRKACB. Front. Pharmacol. 10: 806. 10.3389/fphar.2019.00806 31379578 PMC6658613 · DOI
  147. Wang T. Chen K. Li H. Dong S. Su N. Liu Y. (2015). The feasibility of utilizing plasma MiRNA107 and BACE1 messenger RNA gene expression for clinical diagnosis of amnestic mild cognitive impairment. J. Clin. Psychiatry 76 135– 141. 10.4088/JCP.13m08812 25742200 · DOI
  148. Wang W.-X. Huang Q. Hu Y. Stromberg A. J. Nelson P. T. (2010). Patterns of microRNA expression in normal and early Alzheimer’s disease human temporal cortex: white matter versus gray matter. Acta Neuropathol. 121 193– 205. 10.1007/s00401-010-0756-0 20936480 PMC3073518 · DOI · Paper page
  149. Wang X. Tan L. Lu Y. Peng J. Zhu Y. Zhang Y. (2015). MicroRNA-138 promotes tau phosphorylation by targeting retinoic acid receptor alpha. FEBS Lett. 589 726– 729. 10.1016/j.febslet.2015.02.001 25680531 · DOI
  150. Wang Y. Veremeyko T. Wong A. H. El Fatimy R. Wei Z. Cai W. (2017). Downregulation of miR-132/212 impairs S-nitrosylation balance and induces tau phosphorylation in Alzheimer’s disease. Neurobiol. Aging 51 156– 166. 10.1016/j.neurobiolaging.2016.12.015 28089352 · DOI
  151. Wei H. Xu Y. Xu W. Zhou Q. Chen Q. Yang M. (2018). Serum exosomal miR-223 serves as a potential diagnostic and prognostic biomarker for dementia. Neuroscience 379 167– 176. 10.1016/j.neuroscience.2018.03.016 29559383 · DOI
  152. Wiedrick J. T. Phillips J. I. Lusardi T. A. McFarland T. J. Lind B. Sandau U. S. (2019). Validation of MicroRNA biomarkers for Alzheimer’s disease in human cerebrospinal fluid. J. Alzheimers Dis. 67 875– 891. 10.3233/jad-180539 30689565 PMC6687305 · DOI
  153. Wu D. M. Wen X. Wang Y. J. Han X. R. Wang S. Shen M. (2018). Effect of microRNA-186 on oxidative stress injury of neuron by targeting interleukin 2 through the janus kinase-signal transducer and activator of transcription pathway in a rat model of Alzheimer’s disease. J. Cell. Physiol. 233 9488– 9502. 10.1002/jcp.26843 29995978 · DOI
  154. Wu H. Z. Y. Thalamuthu A. Cheng L. Fowler C. Masters C. L. Sachdev P. (2020). Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer’s disease and controls. Alzheimers Res. Ther. 12: 59. 10.1186/s13195-020-00627-0 32414413 PMC7229622 · DOI
  155. Wu Q. Ye X. Xiong Y. Zhu H. Miao J. Zhang W. (2016). The protective role of microRNA-200c in Alzheimer’s disease pathologies is induced by beta amyloid-triggered endoplasmic reticulum stress. Front. Mol. Neurosci. 9: 140. 10.3389/fnmol.2016.00140 28008308 PMC5143617 · DOI
  156. Wu Y. Xu J. Xu J. Cheng J. Jiao D. Zhou C. (2017). Lower serum levels of miR-29c-3p and miR-19b-3p as biomarkers for Alzheimer’s disease. Tohoku J. Exp. Med. 242 129– 136. 10.1620/tjem.242.129 28626163 · DOI
  157. Xie B. Zhou H. Zhang R. Song M. Yu L. Wang L. (2015). Serum miR-206 and miR-132 as potential circulating biomarkers for mild cognitive impairment. J. Alzheimers Dis. 45 721– 731. 10.3233/JAD-142847 25589731 · DOI
  158. Xu X. F. Wang Y. C. Zong L. Wang X. L. (2019). miR-151-5p modulates APH1a expression to participate in contextual fear memory formation. RNA Biol. 16 282– 294. 10.1080/15476286.2019.1572435 30663934 PMC6380341 · DOI
  159. Yang G. Song Y. Zhou X. Deng Y. Liu T. Weng G. (2015). MicroRNA-29c targets beta-site amyloid precursor protein-cleaving enzyme 1 and has a neuroprotective role in vitro and in vivo. Mol. Med. Rep. 12 3081– 3088. 10.3892/mmr.2015.3728 25955795 · DOI
  160. Yang Q. Zhao Q. Yin Y. (2019). miR-133b is a potential diagnostic biomarker for Alzheimer’s disease and has a neuroprotective role. Exp. Ther. Med. 18 2711– 2718. 10.3892/etm.2019.7855 31572518 PMC6755445 · DOI
  161. Yang T. T. Liu C. G. Gao S. C. Zhang Y. Wang P. C. (2018). The serum exosome derived MicroRNA-135a, -193b, and -384 were potential Alzheimer’s disease biomarkers. Biomed. Environ. Sci. 31 87– 96. 10.3967/bes2018.011 29606187 · DOI
  162. Yilmaz S. G. Erdal M. E. Ozge A. A. Sungur M. A. (2016). Can peripheral MicroRNA expression data serve as epigenomic (upstream) biomarkers of Alzheimer’s disease? OMICS 20 456– 461. 10.1089/omi.2016.0099 27501295 · DOI
  163. Zeng Q. Zou L. Qian L. Zhou F. Nie H. Yu S. (2017). Expression of microRNA222 in serum of patients with Alzheimer’s disease. Mol. Med. Rep. 16 5575– 5579. 10.3892/mmr.2017.7301 28849039 · DOI
  164. Zhang B. Wang L. L. Ren R. J. Dammer E. B. Zhang Y. F. Huang Y. (2016). MicroRNA-146a represses LRP2 translation and leads to cell apoptosis in Alzheimer’s disease. FEBS Lett. 590 2190– 2200. 10.1002/1873-3468.12229 27241555 · DOI
  165. Zhang C. Lu J. Liu B. Cui Q. Wang Y. (2016). Primate-specific miR-603 is implicated in the risk and pathogenesis of Alzheimer’s disease. Aging 8 272– 290. 10.18632/aging.100887 26856603 PMC4789582 · DOI
  166. Zhang J. Hu M. Teng Z. Tang Y. P. Chen C. (2014). Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer’s disease. J. Neurosci. 34 14919– 14933. 10.1523/jneurosci.1165-14.2014 25378159 PMC4220026 · DOI
  167. Zhang J. Liu Z. Pei Y. Yang W. Xie C. Long S. (2018). MicroRNA-322 cluster promotes tau phosphorylation via targeting brain-derived neurotrophic factor. Neurochem. Res. 43 736– 744. 10.1007/s11064-018-2475-1 29464486 · DOI
  168. Zhang Y. Li Q. Liu C. Gao S. Ping H. Wang J. (2016a). MiR-214-3p attenuates cognition defects via the inhibition of autophagy in SAMP8 mouse model of sporadic Alzheimer’s disease. Neurotoxicology 56 139– 149. 10.1016/j.neuro.2016.07.004 27397902 · DOI
  169. Zhang Y. Xing H. Guo S. Zheng Z. Wang H. Xu D. (2016b). MicroRNA-135b has a neuroprotective role via targeting of beta-site APP-cleaving enzyme 1. Exp. Ther. Med. 12 809– 814. 10.3892/etm.2016.3366 27446280 PMC4950157 · DOI
  170. Zhang Y. H. Bai S.-F. Yan J. Q. (2019). Blood circulating miRNAs as biomarkers of Alzheimer’s disease: a systematic review and meta-analysis. Biomark. Med. 13 1045– 1054. 10.2217/bmm-2018-0341 31385521 · DOI
  171. Zhao N. Liu C. C. Qiao W. Bu G. (2018). Apolipoprotein E, receptors, and modulation of Alzheimer’s disease. Biol. Psychiatry 83 347– 357. 10.1016/j.biopsych.2017.03.003 28434655 PMC5599322 · DOI · Paper page
  172. Zheng D. Sabbagh J. J. Blair L. J. Darling A. L. Wen X. Dickey C. A. (2016). MicroRNA-511 binds to FKBP5 mRNA, which encodes a chaperone protein, and regulates neuronal differentiation. J. Biol. Chem. 291 17897– 17906. 10.1074/jbc.M116.727941 27334923 PMC5016178 · DOI
  173. Zhou Y. Deng J. Chu X. Zhao Y. Guo Y. (2019). Role of post-transcriptional control of calpain by miR-124-3p in the development of Alzheimer’s disease. J. Alzheimers Dis. 67 571– 581. 10.3233/jad-181053 30584150 · DOI · Paper page
  174. Zhou Y. Wang Z. F. Li W. Hong H. Chen J. Tian Y. (2018). Protective effects of microRNA-330 on amyloid beta-protein production, oxidative stress, and mitochondrial dysfunction in Alzheimer’s disease by targeting VAV1 via the MAPK signaling pathway. J. Cell. Biochem. 119 5437– 5448. 10.1002/jcb.26700 29369410 · DOI
  175. Zhu L. Li J. Dong N. Guan F. Liu Y. Ma D. (2016). mRNA changes in nucleus accumbens related to methamphetamine addiction in mice. Sci. Rep. 6: 36993. 10.1038/srep36993 27869204 PMC5116666 · DOI
  176. Zhu M. Huang C. Ma X. Wu R. Zhu W. Li X. (2016). Modulation of miR-19 in aluminum-induced neural cell apoptosis. J. Alzheimers Dis. 50 1149– 1162. 10.3233/jad-150763 26836165 · DOI
  177. Zhu Q. B. Unmehopa U. Bossers K. Hu Y. T. Verwer R. Balesar R. (2016). MicroRNA-132 and early growth response-1 in nucleus basalis of Meynert during the course of Alzheimer’s disease. Brain 139 908– 921. 10.1093/brain/awv383 26792551 · DOI
  178. Zong Y. Yu P. Cheng H. Wang H. Wang X. Liang C. (2015). miR-29c regulates NAV3 protein expression in a transgenic mouse model of Alzheimer’s disease. Brain Res. 1624 95– 102. 10.1016/j.brainres.2015.07.022 26212654 · DOI

Cited by

Sorted by citations

Authors
Wei, W., Wang, Z.-Y., Ma, L.-N., Zhang, T.-T., Cao, Y., & Li, H.
Venue
Frontiers in Molecular Neuroscience
Publisher
Frontiers Media SA
Published
2020-08-21
Volume
13
ISSN
1662-5099
DOI
10.3389/fnmol.2020.00160
PMC
PMC7471745
Cited by
102
References
9
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review